The FDA doesn’t always say no with a single word — sometimes it sends a letter. But for Watertown-based Disc Medicine, the Complete Response Letter it received this month for its lead drug bitopertin had the same effect: a hard stop that forced the company to rethink its near-term future, and to part ways with roughly one in five of its employees.
The news broke on March 2, when Disc Medicine informed staff that approximately 20% of the company’s workforce would be eliminated, with the cuts concentrated in commercial operations and corporate functions — precisely the teams the company had been building out in anticipation of a launch that will now have to wait.
The FDA’s objection was specific. Bitopertin, an experimental oral treatment for erythropoietic protoporphyria (EPP) — a rare and painful metabolic disorder triggered by sun exposure — had shown in earlier studies that it could lower levels of PPIX, a key biomarker of the disease. The problem, according to federal regulators, was that the data did not clearly connect those biomarker reductions to the actual sunlight-related outcomes patients experience day to day. In other words: the drug moved the numbers, but the agency wasn’t convinced it was moving the needle for patients in the ways that mattered most.
That distinction — between changing a biomarker and demonstrably improving patient experience — is a line the FDA has been drawing more firmly in recent years, and it has tripped up more than one biotech before Disc.
The company is not without a path forward. Its ongoing Phase 3 APOLLO trial was specifically designed to generate the kind of clinical evidence the FDA is asking for, and management expects topline results in the fourth quarter of 2026. If those results are positive, an updated regulatory decision could come as early as mid-2027. Disc ended 2025 with approximately $791 million in cash and marketable securities, giving it a financial runway that extends into 2029 — meaning this is a setback, not a death sentence.
Still, the human cost of regulatory uncertainty is real. The employees let go were largely part of a commercial infrastructure Disc had been building ahead of what it hoped would be an approved product. Building — and then dismantling — that kind of team is an expensive and demoralizing cycle that has become disturbingly familiar across the Massachusetts biotech corridor.
Disc Medicine is not alone in navigating this moment. Earlier this year, Cambridge-based Seres Therapeutics cut 30% of its workforce after pausing a Phase 2 study, and Watertown’s Lyra Therapeutics went further — shutting down entirely and laying off all 28 remaining employees after reaching a dead end with its own FDA process. Industry trackers noted fewer layoffs in January 2026 compared to the same period in 2025, offering some hope that the sector is stabilizing — but individual company stories like Disc’s are a reminder that stabilization at the macro level offers little comfort when your name is on a termination notice.
For the Greater Boston biotech ecosystem, the broader takeaway is worth sitting with. The region remains the undisputed capital of life sciences innovation in the United States, but the road from promising science to FDA approval has always been brutal — and recent years have made it more so. Industry analysts predict that 2026 layoffs will increasingly stem from traditional factors like drug failures rather than broad sector corrections,— which means the companies with the strongest science and the deepest pockets will survive, while those caught between a promising compound and an uncertain regulatory outcome will face exactly the kind of moment Disc Medicine is living through right now.
